Drug Trial Radar · NCT04460066
A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.
Last checked: Nov 19, 2026Latest source record: May 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
70
Planned (sponsor's estimate)
Start
Nov 18, 2020
Primary completion
Dec 6, 2021
Study completion Jul 15, 2023
Sponsor
- Lead sponsor
- Lee's Pharmaceutical LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jul 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled Ib/Ⅱ clinical study to evaluate the safety and effect of anti-PD-L1 antibody (ZKAB001) in neoadjuvant chemotherapy of esophageal squamous carcinoma in combination with Alb-paclitaxel and cisplatin. The immunotherapy will be given before and after the operation every three weeks.
Conditions
- Esophageal Cancer
Interventions
anti-PD-L1 antibodyDrug
Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
albumin bound paclitaxelDrug
Patients will receive 4 cycles of albumin bound paclitaxel 125mg/m2 on days 1, 8 every 3 weeks .
cisplatinDrug
Patients will receive 4 cycles of cisplatin 75mg/m2 on day 1 every 3 weeks.
placeboDrug
Patients will receive 4 cycles of placebo IV on day 1 every 3 weeks.
radical resection of esophageal carcinomaProcedure
Patients will receive radical resection of esophageal carcinoma after 4 cycles of chemotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- major pathologic response rateTime frame: Two weeks after surgery.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.